

Andrea Patriarca

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9295505/publications.pdf>

Version: 2024-02-01

67
papers

1,417
citations

361413

20
h-index

377865

34
g-index

67
all docs

67
docs citations

67
times ranked

2226
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer. <i>Cancer Discovery</i> , 2020, 10, 1465-1474.	9.4	151
2	Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	4.6	79
3	Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study. <i>Lancet Oncology</i> , The, 2021, 22, 1669-1680.	10.7	73
4	Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL. <i>Blood</i> , 2021, 137, 1365-1376.	1.4	72
5	High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib. <i>Leukemia</i> , 2021, 35, 485-493.	7.2	70
6	Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study. <i>Leukemia</i> , 2019, 33, 1996-2005.	7.2	67
7	Biological and clinical implications of <i>BIRC3</i> mutations in chronic lymphocytic leukemia. <i>Haematologica</i> , 2020, 105, 448-456.	3.5	64
8	Presenting Features and Early Mortality from SARS-CoV-2 Infection in Cancer Patients during the Initial Stage of the COVID-19 Pandemic in Europe. <i>Cancers</i> , 2020, 12, 1841.	3.7	58
9	Time-Dependent COVID-19 Mortality in Patients With Cancer. <i>JAMA Oncology</i> , 2022, 8, 114.	7.1	50
10	Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study. <i>Lancet Oncology</i> , The, 2022, 23, 865-875.	10.7	50
11	Efficacy of recombinant erythropoietin in autoimmune haemolytic anaemia: a multicentre international study. <i>Haematologica</i> , 2021, 106, 622-625.	3.5	39
12	Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study. <i>European Journal of Cancer</i> , 2021, 150, 190-202.	2.8	37
13	Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy. <i>Leukemia</i> , 2020, 34, 488-498.	7.2	35
14	Second cancers in MPN: Survival analysis from an international study. <i>American Journal of Hematology</i> , 2020, 95, 295-301.	4.1	34
15	Use of eltrombopag in aplastic anemia in Europe. <i>Annals of Hematology</i> , 2019, 98, 1341-1350.	1.8	30
16	Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score. , 2021, 9, e002277.		30
17	Precision Medicine Management of Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2020, 12, 642.	3.7	28
18	Atypical Chronic Myeloid Leukemia: Where Are We Now?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6862.	4.1	27

#	ARTICLE	IF	CITATIONS
19	Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome. <i>Blood</i> , 2021, 138, 2002-2005.	1.4	27
20	Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19. <i>Blood Cancer Journal</i> , 2021, 11, 21.	6.2	26
21	Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia. <i>Blood</i> , 2021, 138, 571-583.	1.4	26
22	Investigational drugs for the treatment of diffuse large B-cell lymphoma. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 25-38.	4.1	24
23	Eltrombopag second-line therapy in adult patients with primary immune thrombocytopenia in an attempt to achieve sustained remission off-treatment: results of a phase II, multicentre, prospective study. <i>British Journal of Haematology</i> , 2021, 193, 386-396.	2.5	23
24	Evans syndrome in adults: an observational multicenter study. <i>Blood Advances</i> , 2021, 5, 5468-5478.	5.2	21
25	Targeting p53 in chronic lymphocytic leukemia. <i>Expert Opinion on Therapeutic Targets</i> , 2020, 24, 1239-1250.	3.4	20
26	Is the absence of JAK2 mutation a risk factor for bleeding in essential thrombocythemia? An analysis of 106 patients. <i>Blood Transfusion</i> , 2010, 8, 21-7.	0.4	19
27	Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer. <i>European Journal of Cancer</i> , 2022, 171, 64-74.	2.8	19
28	Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study. <i>Blood</i> , 2020, 135, 381-386.	1.4	18
29	The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index. <i>Leukemia</i> , 2020, 34, 2451-2459.	7.2	14
30	COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry. <i>Journal of the National Cancer Institute</i> , 2022, 114, 979-987.	6.3	14
31	Lymphocyte doubling time in chronic lymphocytic leukemia modern era: a real-life study in 848 unselected patients. <i>Leukemia</i> , 2021, 35, 2325-2331.	7.2	13
32	Predicting the probability of Gaucher disease in subjects with splenomegaly and thrombocytopenia. <i>Scientific Reports</i> , 2021, 11, 2594.	3.3	12
33	The EORTC QLU-C10D was more efficient in detecting clinical known group differences in myelodysplastic syndromes than the EQ-5D-3L. <i>Journal of Clinical Epidemiology</i> , 2021, 137, 31-44.	5.0	11
34	TET2 Mutations in Ph-Negative Myeloproliferative Neoplasms: Identification of Three Novel Mutations and Relationship with Clinical and Laboratory Findings. <i>BioMed Research International</i> , 2013, 2013, 1-5.	1.9	10
35	Validation and reference values of the EORTC QLQ-CML24 questionnaire to assess health-related quality of life in patients with chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 669-678.	1.3	10
36	Long-term follow-up of recovered MPN patients with COVID-19. <i>Blood Cancer Journal</i> , 2021, 11, 115.	6.2	9

#	ARTICLE	IF	CITATIONS
37	An update on: molecular genetics of high-risk chronic lymphocytic leukemia. Expert Review of Hematology, 2020, 13, 109-116.	2.2	7
38	Multiregional sequencing and circulating tumour DNA analysis provide complementary approaches for comprehensive disease profiling of small lymphocytic lymphoma. British Journal of Haematology, 2021, 195, 108-112.	2.5	7
39	Second versus first wave of COVID-19 in patients with MPN. Leukemia, 2022, 36, 897-900.	7.2	7
40	Ponatinib for the treatment of Ph-like acute lymphoblastic leukemia. Leukemia and Lymphoma, 2021, 62, 755-757.	1.3	6
41	Human hematopoietic microenvironments. PLoS ONE, 2021, 16, e0250081.	2.5	6
42	Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network. Frontiers in Oncology, 2021, 11, 739171.	2.8	6
43	Anti-CD22 antibodies induce clinical refractoriness by inhibiting the enzyme catalytic activity. Hematological Oncology, 2020, 38, 204-206.	1.7	6
44	A randomized clinical study on the impact of Comprehensive Geriatric Assessment (CGA) based interventions on the quality of life of elderly, frail, onco-hematologic patients candidate to anticancer therapy: protocol of the ONCO-Aging study. BMC Geriatrics, 2021, 21, 320.	2.7	5
45	Effective Treatment of Cold Agglutinin Disease/Cold Agglutinin Syndrome with Ibrutinib: An International Case Series. Blood, 2020, 136, 29-30.	1.4	5
46	Patterns of neutralizing humoral response to SARS-CoV-2 infection among hematologic malignancy patients reveal a robust immune response in anti-cancer therapy-naïve patients. Blood Cancer Journal, 2022, 12, 8.	6.2	5
47	Physicians' Perceptions of Clinical Utility of a Digital Health Tool for Electronic Patient-Reported Outcome Monitoring in Real-Life Hematology Practice. Evidence From the GIMEMA-ALLIANCE Platform. Frontiers in Oncology, 2022, 12, 826040.	2.8	5
48	Specialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection: a European perspective. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110422.	3.2	4
49	Intravascular lymphoma: from vessels to genes. Blood, 2021, 137, 1438-1439.	1.4	4
50	Precision Medicine in Systemic Mastocytosis. Medicina (Lithuania), 2021, 57, 1135.	2.0	4
51	The Biology of Chronic Lymphocytic Leukemia. Cancer Journal (Sudbury, Mass), 2021, 27, 266-274.	2.0	3
52	Eltrombopag As Second Line Therapy in Adult Patients with Primary Immune Thrombocytopenia (ITP) in Attempt to Achieve Long-Term Remission. Preliminary Analysis of a Phase II, Multicenter, Prospective Study By Gimema Group (the ESTIT Study). Blood, 2018, 132, 1135-1135.	1.4	3
53	Evans' Syndrome in Adults: An Observational Multicentre Study. Blood, 2020, 136, 27-28.	1.4	3
54	A step ahead toward precision medicine for chronic lymphocytic leukemia. Haematologica, 2020, 105, 2352-2355.	3.5	3

#	ARTICLE	IF	CITATIONS
55	Stiffer Spleen Predicts Higher Bone Marrow Fibrosis and Higher JAK2 Allele Burden in Patients With Myeloproliferative Neoplasms. <i>Frontiers in Oncology</i> , 2021, 11, 777730.	2.8	3
56	Assessing prognosis of chronic lymphocytic leukemia using biomarkers and genetics. <i>Expert Opinion on Orphan Drugs</i> , 2020, 8, 329-342.	0.8	2
57	High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity. <i>International Journal of Hematology</i> , 2020, 112, 141-146.	1.6	2
58	Genetic Predisposition to Myelodysplastic Syndromes: A Challenge for Adult Hematologists. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2525.	4.1	2
59	Impact of the G8 score on the outcome of a cohort of elderly patients with solid or hematological malignancies.. <i>Journal of Clinical Oncology</i> , 2021, 39, 12038-12038.	1.6	2
60	Predictors of Response to Erythropoietin in Autoimmune Hemolytic Anemia. <i>Blood</i> , 2019, 134, 3516-3516.	1.4	2
61	Frequency of Thrombosis Is Higher in MPN Patients Who Develop Second Cancer Than in Controls. <i>Blood</i> , 2019, 134, 4170-4170.	1.4	2
62	An acquired factor V inhibitor induced uncontrolled bleeding in a postsurgery patient. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, 98-101.	0.5	1
63	Visualizing Normal and Malignant Human Stem and Progenitor Cells in Histological Sections. , 2020, , 50-61.		1
64	Mutations of the <i>Exportin 1 (XPO1)</i> Gene Predict Shorter Time to First Treatment in 1092 Early Stage Chronic Lymphocytic Leukemia Patients. <i>Training/Validation Study. Blood</i> , 2020, 136, 31-32.	1.4	1
65	Cerebrospinal fluid xanthochromia after pegasparginase hepatotoxicity in <i>B-cell</i> acute lymphoblastic leukemia. <i>Clinical Case Reports (discontinued)</i> , 2020, 8, 2293-2294.	0.5	0
66	Predictive Factors for Overall Survival in Chronic Myeloid Leukemia Patients: An Analysis By the Gimema Cml Italian Study. <i>Blood</i> , 2020, 136, 47-48.	1.4	0
67	Thrombopoietin receptor agonists in adult Evans syndrome: an international multicenter experience.. <i>Blood</i> , 0, , .	1.4	0